Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7778)
All Articles published online
|
Publishing Process of This Article
|
Aug 6, 2019 (publication date) through Nov 3, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Kaito A, Kuwata T, Tokunaga M, Shitara K, Sato R, Akimoto T, Kinoshita T. HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer. World J Clin Cases 2019; 7(15): 1964-1977 [PMID: 31423428 DOI: 10.12998/wjcc.v7.i15.1964] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v7/i15/1964.htm |
| Number | Citing Articles |
| 1 |
Kazuki Kanayama, Hiroshi Imai, Eri Usugi, Chise Matsuda, Masako Ichishi, Yoshifumi S. Hirokawa, Masatoshi Watanabe. Cancer‐related gene mutations and intratumoral genetic heterogeneity in human epidermal growth factor receptor 2 heterogeneous gastric cancer. Pathology International 2020; 70(11): 865 doi: 10.1111/pin.13004
|
| 2 |
Meng He, Zi-fan Chen, Song Liu, Yang Chen, Huan Zhang, Li Zhang, Jie Zhao, Jie Yang, Xiao-tian Zhang, Lin Shen, Jian-bo Gao, Bin Dong, Lei Tang. Deep learning model based on multi-lesion and time series CT images for predicting the benefits from anti-HER2 targeted therapy in stage IV gastric cancer. Insights into Imaging 2024; 15(1) doi: 10.1186/s13244-024-01639-2
|
| 3 |
Kyunghye Bang, Jaekyung Cheon, Young Soo Park, Hyung-Don Kim, Min-Hee Ryu, Yangsoon Park, Meesun Moon, Hyungeun Lee, Yoon-Koo Kang. Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab. Gastric Cancer 2022; 25(4): 794 doi: 10.1007/s10120-022-01298-6
|
| 4 |
Jeesun Yoon, Do-Youn Oh. HER2-targeted therapies beyond breast cancer — an update. Nature Reviews Clinical Oncology 2024; 21(9): 675 doi: 10.1038/s41571-024-00924-9
|
| 5 |
Yoshiaki Nakamura, Akihito Kawazoe, Florian Lordick, Yelena Y. Janjigian, Kohei Shitara. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nature Reviews Clinical Oncology 2021; 18(8): 473 doi: 10.1038/s41571-021-00492-2
|
| 6 |
Takeshi Kuwata. Molecular classification and intratumoral heterogeneity of gastric adenocarcinoma. Pathology International 2024; 74(6): 301 doi: 10.1111/pin.13427
|
| 7 |
Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Alba Martinez-Torron, Maria Alsina, Ana Custodio, Olbia Serra, Diego Cacho Lavin, María Luisa Limón, Tamara Sauri, Flora López, Laura Visa, Mónica Granja, Nieves Martínez Lago, Virginia Arrazubi, Rosario Vidal Tocino, Raquel Hernandez, Gema Aguado, Juana María Cano, Alfonso Martín Carnicero, Monserrat Mangas, Paola Pimentel, Ana Fernández Montes, Ismael Macias Declara, Federico Longo, Avinash Ramchandani, Marta Martín Richard, Alicia Hurtado, Aitor Azkarate, Carolina Hernández Pérez, Raquel Serrano, Javier Gallego. External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry. Therapeutic Advances in Medical Oncology 2021; 13 doi: 10.1177/17588359211019672
|
| 8 |
Hoon Jai Chun, Seun Ja Park, Yun Jeong Lim, Si Young Song. Gastrointestinal Cancer. 2023; : 13 doi: 10.1007/978-981-99-0815-8_3
|
| 9 |
Debora Basile, Francesca Simionato, Alessandro Cappetta, Silvio Ken Garattini, Giandomenico Roviello, Giuseppe Aprile. State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer. Biologics: Targets and Therapy 2021; : 451 doi: 10.2147/BTT.S290323
|
| 10 |
In-Ho Kim. Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond. Journal of Gastric Cancer 2024; 24(1): 29 doi: 10.5230/jgc.2024.24.e6
|
| 11 |
Li-Fei Sun, Kun Yang, Yi-Gao Wang, Yu-Xin Liu, Pei-Xian Hou, Zheng-Hao Lu, Xiao-Long Chen, Wei-Han Zhang, Zong-Guang Zhou, Xian-Ming Mo, Jian-Kun Hu. The Role of HER2 in Self-Renewal, Invasion, and Tumorigenicity of Gastric Cancer Stem Cells. Frontiers in Oncology 2020; 10 doi: 10.3389/fonc.2020.01608
|
| 12 |
Xiaoting Ma, Liyan Xue, Kai Ou, Xiu Liu, JunLin Chen, Lizhen Gao, Lin Yang. Significant effect of posterior line treatment of HER2 positive advanced gastric cancer: A case report. Heliyon 2024; 10(7): e28923 doi: 10.1016/j.heliyon.2024.e28923
|
| 13 |
Ryan Sappenfield, Eric Mehlhaff, Devon Miller, Johnathan E. Ebben, Nataliya V. Uboha. Current and Future Biomarkers in Esophagogastric Adenocarcinoma. Journal of Gastrointestinal Cancer 2024; 55(2): 549 doi: 10.1007/s12029-023-01007-1
|
| 14 |
Katharina Kolbe, Ivonne Haffner, Katrin Schierle, Dieter Maier, Birgitta Geier, Birgit Luber, Hendrik Bläker, Christian Wittekind, Florian Lordick. Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study. Journal of Cancer Research and Clinical Oncology 2023; 149(3): 1319 doi: 10.1007/s00432-022-04208-6
|
| 15 |
Maria Alsina, Virginia Arrazubi, Marc Diez, Josep Tabernero. Current developments in gastric cancer: from molecular profiling to treatment strategy. Nature Reviews Gastroenterology & Hepatology 2023; 20(3): 155 doi: 10.1038/s41575-022-00703-w
|
| 16 |
Charalampos Theocharopoulos, Ioannis A. Ziogas, Charalampos-Christos Douligeris, Andreas Efstathiou, Epaminondas Kolorizos, Dimitrios C. Ziogas, Elissaios Kontis. Antibody-drug conjugates for hepato-pancreato-biliary malignancies: “Magic bullets” to the rescue?. Cancer Treatment Reviews 2024; 129: 102806 doi: 10.1016/j.ctrv.2024.102806
|
| 17 |
Jeremy Chuang, Samuel Klempner, Kevin Waters, Katelyn Atkins, Joseph Chao, May Cho, Andrew Hendifar, Alexandra Gangi, Miguel Burch, Pareen Mehta, Jun Gong. Therapeutic Advances and Challenges in the Management of HER2-Positive Gastroesophageal Cancers. Diseases 2022; 10(2): 23 doi: 10.3390/diseases10020023
|
| 18 |
Zimin Liu, Mingpeng Shi, Xiaoxiao Li, Shanai Song, Ning Liu, Haiwei Du, Junyi Ye, Haiyan Li, Zhou Zhang, Lu Zhang. HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma. Journal of Cancer Research and Clinical Oncology 2021; 147(5): 1315 doi: 10.1007/s00432-021-03522-9
|
| 19 |
Brian C. Grieb, Rajiv Agarwal. HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles. Current Treatment Options in Oncology 2021; 22(10) doi: 10.1007/s11864-021-00884-7
|
| 20 |
Juliette Palle, Adrien Rochand, Simon Pernot, Claire Gallois, Julien Taïeb, Aziz Zaanan. Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives. Drugs 2020; 80(4): 401 doi: 10.1007/s40265-020-01272-5
|
| 21 |
Xiaoyi Chong, Yuezong Bai, Hua Liu, Zhengqing Yan, Lin Cong, Jifang Gong, Yakun Wang, Hui Chen, Jinping Cai, Shiqing Chen, Xiaochen Zhao, Cheng Zhang, Xiaotian Zhang. The Efficacy and Plasma ctDNA as a Biomarker of Dual PD-1 and HER2 Blockade in HER2-Positive Gastric or Gastroesophageal Junction Cancers. SSRN Electronic Journal 2022; doi: 10.2139/ssrn.4186786
|
| 22 |
Chenzhe Ma, Xiao Wang, Jiwu Guo, Bo Yang, Yumin Li. Challenges and future of HER2-positive gastric cancer therapy. Frontiers in Oncology 2023; 13 doi: 10.3389/fonc.2023.1080990
|
| 23 |
Wengui Shi, Gengyuan Zhang, Zhijian Ma, Lianshun Li, Miaomiao Liu, Long Qin, Zeyuan Yu, Lei Zhao, Yang Liu, Xue Zhang, Junjie Qin, Huili Ye, Xiangyan Jiang, Huinian Zhou, Hui Sun, Zuoyi Jiao. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer. Nature Communications 2021; 12(1) doi: 10.1038/s41467-021-23053-8
|
| 24 |
Nobuyoshi Hiraoka, Hiroaki Nitta, Akihiro Ohba, Hiroshi Yoshida, Chigusa Morizane, Takuji Okusaka, Satoshi Nara, Minoru Esaki, Yoji Kishi, Kazuaki Shimada. Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer. Human Pathology 2020; 105: 9 doi: 10.1016/j.humpath.2020.08.006
|
| 25 |
Gianluca Businello, Valentina Angerilli, Sara Lonardi, Francesca Bergamo, Michele Valmasoni, Fabio Farinati, Edoardo Savarino, Gaya Spolverato, Matteo Fassan. Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter. Updates in Surgery 2023; 75(2): 291 doi: 10.1007/s13304-022-01330-5
|
| 26 |
Maluki Radford, Hassan Abushukair, Stijn Hentzen, Ludimila Cavalcante, Anwaar Saeed. Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era. Journal of Immunotherapy and Precision Oncology 2023; 6(3): 150 doi: 10.36401/JIPO-22-36
|
| 27 |
Verena M. Prade, Thomas Kunzke, Annette Feuchtinger, Maria Rohm, Birgit Luber, Florian Lordick, Achim Buck, Axel Walch. De novo discovery of metabolic heterogeneity with immunophenotype-guided imaging mass spectrometry. Molecular Metabolism 2020; 36: 100953 doi: 10.1016/j.molmet.2020.01.017
|
| 28 |
Akio Kaito, Takeshi Kuwata, Masanori Tokunaga, Kohei Shitara, Reo Sato, Tetsuo Akimoto, Takahiro Kinoshita. Erratum: Author’s Affiliation Correction. Type II human epidermal growth factor receptor heterogeneity is a poor prognosticator for type II human epidermal growth factor receptor positive gastric cancer (World J Clin Cases 2019; Aug 6; 7 (15): 1964-1977). World Journal of Clinical Cases 2020; 8(21): 5494-5495 doi: 10.12998/wjcc.v8.i21.5494
Abstract(790) |
Core Tip(518) |
Full Article(HTML)(1680)
|
Full Article (PDF)-775K(218)
|
Full Article (Word)-22K(239)
|
Audio-1594K(4)
|
Answering Reviewers-118K(88)
|
Full Article (XML)-12K(24)
|
Times Cited (0)
|
Total Visits (5394)
|
Open
|
| 29 |
Paula Jimenez-Fonseca, Victoria Foy, Sophie Raby, Alberto Carmona-Bayonas, Lola Macía-Rivas, Virginia Arrazubi, Diego Cacho Lavin, Raquel Hernandez San Gil, Ana Custodio, Juana María Cano, Ana Fernández Montes, Oriol Mirallas, Ismael Macias Declara, Rosario Vidal Tocino, Laura Visa, María Luisa Limón, Paola Pimentel, Nieves Martínez Lago, Tamara Sauri, Marta Martín Richard, Monserrat Mangas, Mireia Gil Raga, Aitana Calvo, Pablo Reguera, Mónica Granja, Alfonso Martín Carnicero, Carolina Hernández Pérez, Paula Cerdá, Lucía Gomez Gonzalez, Francisco Garcia Navalon, Vilma Pacheco Barcia, David Gutierrez Abad, Maribel Ruiz Martín, Jamie Weaver, Wasat Mansoor, Javier Gallego. The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy. Therapeutic Advances in Medical Oncology 2023; 15 doi: 10.1177/17588359231157641
|
| 30 |
Caroline Fong, Ian Chau. HER2 Inhibition in Gastric Cancer—Novel Therapeutic Approaches for an Established Target. Cancers 2022; 14(15): 3824 doi: 10.3390/cancers14153824
|
| 31 |
Kyungeun Kim, Kris Ylaya, Candice Perry, Mi-Yeon Lee, Jeong Won Kim, Joon-Yong Chung, Stephen M. Hewitt. Quality Assessment of Proteins and RNA Following Storage in Archival Formalin-Fixed Paraffin-Embedded Human Breast Cancer Tissue Microarray Sections. Biopreservation and Biobanking 2023; 21(5): 493 doi: 10.1089/bio.2022.0090
|
| 32 |
Isabel Porth, Daniela Hirsch, Yonca Ceribas, Philip Weidner, Wilko Weichert, Thorsten Oliver Götze, Sven Perner, Kim Luley, Christian Moritz Heyer, Carolina de la Torre, Ralf-Dieter Hofheinz, Sylvie Lorenzen, Timo Gaiser. Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma. European Journal of Cancer 2023; 183: 119 doi: 10.1016/j.ejca.2023.01.022
|
| 33 |
Elisabeth G. E. de Vries, Josef Rüschoff, Martijn Lolkema, Josep Tabernero, Luca Gianni, Emile Voest, Derk Jan A. de Groot, Daniel Castellano, Gilles Erb, Julia Naab, Margarita Donica, Regula Deurloo, Michiel S. van der Heijden, Giuseppe Viale. Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. Cancer Medicine 2023; 12(11): 12071 doi: 10.1002/cam4.5893
|
| 34 |
Seiichiro Mitani, Hisato Kawakami. Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance. Cancers 2020; 12(2): 400 doi: 10.3390/cancers12020400
|
| 35 |
Karen L. Talia, Natalie Banet, Natalia Buza. The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma. Pathology 2023; 55(1): 8 doi: 10.1016/j.pathol.2022.11.004
|
| 36 |
Diana B. Peckys, Daniel Gaa, Niels de Jonge. Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy. Cells 2021; 10(11): 3244 doi: 10.3390/cells10113244
|
| 37 |
Yao Chang, Delong Zhao, Zicheng Wang, Kejia Zhu, Andong Guo, Jishuang Cao, Chenrui Wu, Sentai Ding. Expression of HER2 in urothelial carcinoma and its significance. Current Urology 2024; doi: 10.1097/CU9.0000000000000249
|
| 38 |
Jane E. Rogers, Kohei Yamashita, Matheus Sewastjanow-Silva, Allison Trail, Rebecca E. Waters, Jaffer Ajani. Human Epidermal Growth Factor Receptor-2 Gastric Adenocarcinoma: Expanding Therapy of a Recognized Target. Cancers 2023; 15(21): 5180 doi: 10.3390/cancers15215180
|
| 39 |
Carmine Valenza, Lorenzo Guidi, Elena Battaiotto, Dario Trapani, Andrea Sartore Bianchi, Salvatore Siena, Giuseppe Curigliano. Targeting HER2 heterogeneity in breast and gastrointestinal cancers. Trends in Cancer 2023; doi: 10.1016/j.trecan.2023.11.001
|
| 40 |
Cathy E. Richards, Katherine M. Sheehan, Elaine W. Kay, Charlotta Hedner, David Borg, Joanna Fay, Anthony O’Grady, Arnold D. K. Hill, Karin Jirström, Ann M. Hopkins. Development of a Novel Weighted Ranking Method for Immunohistochemical Quantification of a Heterogeneously Expressed Protein in Gastro-Esophageal Cancers. Cancers 2021; 13(6): 1286 doi: 10.3390/cancers13061286
|
| 41 |
Silvia Pelligra, Natalia Buza, Pei Hui, Stefania Bellone, Burak Zeybek, Elena Ratner, Peter E. Schwartz, Giovanni Scambia, Alessandro D. Santin. Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma. Gynecologic Oncology Reports 2020; 32: 100554 doi: 10.1016/j.gore.2020.100554
|